

3 March 2017

Our Ref: RFI 19490

Dear

**Freedom of Information Act 2000
Take up of Biosimilar Benepali**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for the information relating to the above which you requested on 26 January 2017.

A response to each of the questions raised has been provided by the Woman and Acute Child Health Directorate and is attached in Appendix A.

Under the terms of the legislation, if you are unhappy with this response you have the right to seek a review within the Trust in the first instance. If you wish to do so, please write to me at the address below.

If after such a review you are still unhappy with the response, you have the right to appeal to the Information Commissioner who will undertake an independent review. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, SK9 5AF.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Laura Algie
Senior Manager
Risk Management & Governance Department

*I wish to learn more about your hospital's take-up of the rheumatoid arthritis drug Biosimilar Benepali
(http://www.pharmatimes.com/news/biogen_launches_enbrel_biosimilar_benepali_in_the_uk_1020383).*

Please can you provide information on the following:

Q1. *Total number of patients being treated for rheumatoid arthritis*

A1. This information is not recorded by the Trust.

Q2. *Total number of patients suitable for Benepali*

A2. This information is not recorded by the Trust.

Q3. *Total number of patients that have been prescribed Benepali so far*

A3. No patients have been prescribed Benepali so far.

Q4. *Expected number of patients to be on Benepali in 12 months' time (if predicted)*

A4. No decision has been made yet regarding use of Benepali

Policy on Benepali:

Any other information on decisions made regarding Benepali? Please provide

Q5. *Is your hospital automatically switching patients from Etanercept to Benepali?*

A5. No.

Q6. *Are your rheumatologists using Benepali as a first line anti-TNF treatment in TNF-naive patients?*

A6. No.

Q7. *How much do you anticipate saving per year by switching from Etanercept to Benepali?*

A7. There are no current plans to switch.